Acorda Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Acorda Therapeutics Inc (ACORQ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Acorda Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 116M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-29.8% annualized vs trailing 12 months).
- Peer revenue share: Acorda Therapeutics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ACORQ Sales vs. its Competitors, Q1 2024
Acorda Therapeutics Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs -8.9% for Acorda Therapeutics Inc. Acorda Therapeutics Inc's share of combined industry revenue moved from 0.06% to 0.05%, a loss of 0.02 percentage points.
Acorda Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Acorda Therapeutics Inc | No | No | No | No |
| High-Confidence Competitors (7) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ACORQ Stock Performance relative to its Competitors
ACORQ Stock Performance relative to High-Confidence Competitors
ACORQ Stock Performance relative to Similar Growth & Profitability Competitors
Acorda Therapeutics Inc's Comment on Competition and Industry Peers
Acorda Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis AG | Named by the company | 85% |
| PHGEU | Named by the company | 85% |
| Impel Neuropharma | Named by the company | 85% |
| Vectura Group plc | Named by the company | 85% |
| Allergan, Inc. | Named by the company | 85% |
| Pulmatrix, Inc. | Named by the company | 85% |
| Voyager Therapeutics Inc | Named by the company | 85% |
| MannKind Corporation | Named by the company | 85% |
| Biomx Inc | Named by the company | 85% |
| GlaxoSmithKline plc | Named by the company | 85% |
| PureIMS B.V. | Named by the company | 85% |
| Alexza Pharmaceuticals, Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Acorda Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.